- Home
- NVGS vs VIR Comparison
NVGS vs VIR Comparison
Compare NVGS & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVGS
- VIR
- Stock Information
- Founded
- NVGS 1997
- VIR 2016
- Country
- NVGS United Kingdom
- VIR United States
- Employees
- NVGS N/A
- VIR N/A
- Industry
- NVGS Marine Transportation
- VIR Biotechnology: Pharmaceutical Preparations
- Sector
- NVGS Consumer Discretionary
- VIR Health Care
- Exchange
- NVGS Nasdaq
- VIR Nasdaq
- Market Cap
- NVGS 1.1B
- VIR 1.0B
- IPO Year
- NVGS N/A
- VIR 2019
- Fundamental
- Price
- NVGS $15.94
- VIR $6.95
- Analyst Decision
- NVGS Strong Buy
- VIR Buy
- Analyst Count
- NVGS 3
- VIR 5
- Target Price
- NVGS $22.00
- VIR $36.40
- AVG Volume (30 Days)
- NVGS 190.2K
- VIR 1.6M
- Earning Date
- NVGS 11-06-2024
- VIR 10-31-2024
- Dividend Yield
- NVGS 1.26%
- VIR N/A
- EPS Growth
- NVGS 13.48
- VIR N/A
- EPS
- NVGS 1.12
- VIR N/A
- Revenue
- NVGS $564,280,000.00
- VIR $78,618,000.00
- Revenue This Year
- NVGS $3.05
- VIR N/A
- Revenue Next Year
- NVGS $2.17
- VIR N/A
- P/E Ratio
- NVGS $14.36
- VIR N/A
- Revenue Growth
- NVGS 5.99
- VIR N/A
- 52 Week Low
- NVGS $13.85
- VIR $6.56
- 52 Week High
- NVGS $18.18
- VIR $13.09
- Technical
- Relative Strength Index (RSI)
- NVGS 50.43
- VIR 36.25
- Support Level
- NVGS $15.25
- VIR $9.48
- Resistance Level
- NVGS $16.57
- VIR $10.13
- Average True Range (ATR)
- NVGS 0.39
- VIR 0.57
- MACD
- NVGS 0.06
- VIR -0.32
- Stochastic Oscillator
- NVGS 52.27
- VIR 10.05
About NVGS Navigator Holdings Ltd. (Marshall Islands)
Navigator Holdings Ltd owns and operates liquefied gas carriers, which include a fleet of handysize liquefied gas carriers. The company also owns a share in an ethylene export marine terminal at Morgan's Point, Texas on the Houston Ship Channel (the Ethylene Export Terminal) through a joint venture (the Export Terminal Joint Venture).
About VIR Vir Biotechnology Inc.
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.